Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23663758 | 1.00 | NR1H2 (0.51) | NR1H2GPR119DDB1CRBNHPGD | |
| SCHEMBL22010186 | 1.00 | NR1H2 (0.51) | NR1H2GPR119DDB1CRBNHPGD | |
| SCHEMBL1135431 | 1.00 | NR1H2 (0.51) | NR1H2GPR119DDB1CRBNHPGD | |
| SCHEMBL1135375 | 1.00 | NR1H2 (0.51) | NR1H2GPR119DDB1CRBNHPGD | |
| SCHEMBL1135376 | 1.00 | NR1H2 (0.51) | NR1H2GPR119DDB1CRBNHPGD | |
| SCHEMBL22689240 | 0.91 | NR1H2 (0.49) | NR1H2GPR119DDB1CRBNHPGD | |
| SCHEMBL3650512 | 0.91 | NR1H2 (0.49) | NR1H2GPR119DDB1CRBNHPGD | |
| SCHEMBL22695207 | 0.91 | NR1H2 (0.49) | NR1H2GPR119DDB1CRBNHPGD | |
| SCHEMBL23700689 | 0.91 | GPR119 (0.46) | NR1H2GPR119HPGDJAK2JAK1 | |
| SCHEMBL20186727 | 0.91 | GPR119 (0.46) | NR1H2GPR119HPGDJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519412-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-25 | — | — | US | disclosed |
| EP-3519412-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | Mission Therapeutics Limited (GB) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018060742-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | NR1H2 2355/4885GPR119 1358/4885DDB1 998/4885 |
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP1, USP28 | NR1H2 3659/4885GPR119 3721/4885DDB1 274/4885 |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | NR1H2 3745/4885GPR119 3643/4885DDB1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.